glp 1 compound news 🚨 BREAKING GLP-1 #tirzepatide #semaglutide Compound versions of GLP-1 drugs

Patients usually get more value from medical review, fit assessment, and follow-up planning than from choosing a medication based only on headlines or social posts.

One trial showed participants taking 7.2mg weekly losing on average 18.7%, with many reaching 20-25% weight loss thresholds

"With Foundayo, we now have an oral option that delivered an average of 12.4% weight loss at the highest dose in clinical trials addressing both the clinical realities of obesity and the practical challenges patients face every day." Supported by the ATTAIN clinical trial programme, Foundayo was proven to help people lose weight and keep it off

CTL: cytotoxic T lymphocyte

Insulin Dose Reduction at GLP-1 RA Initiation In the SUSTAIN-5 trial (N=397), patients on semaglutide 1 mg plus basal insulin experienced a symptomatic hypoglycemia rate of 11.3%, versus 1.1% in the semaglutide-plus-metformin-only arm [6]

*Verified by process control